The ADX-102-UV-005 research study is seeking volunteers to assess the safety and effectiveness of an investigational treatment for adults with non-infectious anterior uveitis.
The study is a randomized, double-masked, vehicle-controlled Phase 3 study to evaluate the safety and efficacy of ADX-102 Topical Ophthalmic Solution for the treatment of patients with non-infectious anterior uveitis. Eligible Subjects will be randomly assigned either ADX-102 Topical Ophthalmic Solution (0.5%) or placebo and be instructed to administer daily doses for approximately 4 weeks. Approximately 100 eligible subjects will be enrolled in this study.
Participation in the ADX-102-UV-005 study will involve 6 clinic visits and the total study duration is approximately 5 weeks. No medical insurance is required for participation in this study.
If qualified, participants may receive:
More Information about the Study:
If you feel that you may be eligible for this study and are interested in participating more information is available here: https://www.clinicaltrials.gov/ct2/show/NCT03131154?term=adx-102&rank=1
More Information about the Sponsor:
Please visit www.aldeyra.com.
Click here to listen to
Uveitis and Steroid-Sparing Therapy
Presented by C. Stephen Foster, MD, FACS, FACR
Audio-Digest Ophthalmology Volume 56, Issue 15
This site complies with the HONcode standard for trustworthy health information: verify here.